Fundraising Fox

Neurovance

Cambridge, US · Founded 2011 · Delaware corporation · 1 known investors

Biotech

Founders & leadership

GB
Gregg BeloffActing Chief Financial Officer
WT
William T. PappafotopoulosVice President, Finance and Administration
JB
Jeffrey BaileyExecutive Chairman
AA
Anthony A. McKinneyChief Development Officer
FP
Franklin P. BymasterExecutive
TA
Thomas A. SheaExecutive
PT
Pierre TranExecutive

Board

CM
Campbell MurrayBoard director
DO
Daniel OmsteadBoard director
BS
Brigitte SmithBoard director
PW
Paul WeissBoard director
AB
Andrew BakerBoard director

Investors · 1

Novartis Venture FundreportedBasel · $5M – $25M

Reported raises · per SEC filings

Form D private placements

$54.7M disclosed across 5 rounds · 2012–2016

▶$554.3KraisedJan 2017 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Timothy J. BarberichDirector
  • Anthony A. McKinneyExecutive Officer
  • Albert L. SokolExecutive Officer
  • Paul WeissDirector
  • Brigitte SmithDirector
  • Jeffrey BaileyExecutive Officer, Director
  • Daniel OmsteadDirector
  • Campbell MurrayDirector
  • William T. PappafotopoulosExecutive Officer
  • Brian GoffExecutive Officer, Director
  • Gregg BeloffExecutive Officer
Offering amount
$554.3K
Amount sold
$554.3K
First sale
Dec 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7.5MraisedDec 2016 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Albert L. SokolExecutive Officer
  • Campbell MurrayDirector
  • Daniel OmsteadDirector
  • Timothy J. BarberichDirector
  • Gregg BeloffExecutive Officer
  • Brigitte SmithDirector
  • William T. PappafotopoulosExecutive Officer
  • Paul WeissDirector
  • Jeffrey BaileyExecutive Officer, Director
  • Anthony A. McKinneyExecutive Officer
Offering amount
$16M
Amount sold
$7.5M
First sale
Feb 2016
Incorporated
Corporation, Delaware, 2011
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$26.5MraisedJun 2015 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • William T. PappafotopoulosExecutive Officer
  • Albert L. SokolExecutive Officer
  • Brigitte RobertsonExecutive Officer
  • Campbell MurrayDirector
  • Timothy J. BarberichDirector
  • Daniel OmsteadDirector
  • Franklin P. BymasterExecutive Officer
  • Anthony A. McKinneyExecutive Officer, Director
  • Brigitte SmithDirector
  • Paul WeissDirector
Offering amount
$26.5M
Amount sold
$26.5M
Minimum investment
$16.3K
First sale
Oct 2012
Incorporated
Corporation, Delaware, 2011
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$20MraisedMar 2015 · 7 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Campbell MurrayDirector
  • Daniel OmsteadDirector
  • Anthony A. McKinneyExecutive Officer, Director
  • William T. PappafotopoulosExecutive Officer
  • TImothy J. BarberichDirector
  • Albert L. SokolExecutive Officer
  • Franklin P. BymasterExecutive Officer
  • Walter PiskorskiExecutive Officer
  • Brigitte SmithDirector
  • Brigitte RobertsonExecutive Officer
  • Paul WeissDirector
Offering amount
$20M
Amount sold
$20M
Minimum investment
$16.3K
First sale
Oct 2012
Incorporated
Corporation, Delaware, 2011
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$163.5KraisedMar 2012 · 6 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Timothy J. BarberichDirector
  • Paul WeissDirector
  • Frank GentileDirector
  • Franklin P. BymasterExecutive Officer
  • Thomas A. SheaExecutive Officer
  • Campbell MurrayDirector
  • Anthony A. McKinneyExecutive Officer, Director
  • Pierre TranExecutive Officer
  • Andrew BakerDirector
Offering amount
$478.1K
Amount sold
$163.5K
Minimum investment
$2.5K
First sale
Mar 2012
Incorporated
Corporation, Delaware, 2011
Federal exemptions
06
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Neurovance raises $6.3M to focus on ADHD drug - Boston Business Journalbizjournals.com · Apr 2014BioCentury - Euthymics' Neurovance spinout raises $7Mbiocentury.com · Oct 2012Neurovance Emerges From Stealth With $7 Million for ADHD - BioSpacebiospace.com · Oct 2012

Frequently asked questions

Who are Neurovance's investors?
Neurovance's investors include Novartis Venture Fund.
How much funding has Neurovance raised?
Neurovance has disclosed $54.7M raised across 5 rounds.
Where is Neurovance headquartered?
Neurovance is headquartered in Cambridge, US.